Trials / Withdrawn
WithdrawnNCT05444153
Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
Efficacy and Safety of Early Initiation of Oral Semaglutide 50 mg Once Daily Versus Empagliflozin 25 mg Once Daily in Younger Patients With Newly Diagnosed Type 2 Diabetes and Obesity
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study compares the medicines semaglutide and empagliflozin in people with newly diagnosed type 2 diabetes and obesity. The study will look mainly at how well the blood sugar and body weight are controlled when participants are taking the study medicine. Participants will either get semaglutide tablets or empagliflozin tablets. Which treatment participants get is decided by chance. Participants will get one tablet per day for 2 years. The study will last for about 2 years and 8 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide | Participants will receive 1 tablet of oral semaglutide once daily. |
| DRUG | Empagliflozin | Participants will receive 1 tablet of empagliflozin once daily. |
Timeline
- Start date
- 2022-10-06
- Primary completion
- 2024-10-02
- Completion
- 2025-08-29
- First posted
- 2022-07-05
- Last updated
- 2022-11-14
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05444153. Inclusion in this directory is not an endorsement.